AMXT-1501(AMXT-1501) - 在研适应症：脑干胶质瘤，弥漫内生性脑桥神经胶质瘤，室管膜母细胞瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

+ [2]

靶点-

作用方式

抑制剂

作用机制

多胺转运抑制剂

治疗领域

肿瘤神经系统疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

脑干胶质瘤弥漫内生性脑桥神经胶质瘤室管膜母细胞瘤+ [8]

非在研适应症

乳腺癌结直肠癌组蛋白H3中K27M点突变的弥漫性中线胶质瘤+ [11]

原研机构

Aminex Therapeutics, Inc.

在研机构

Aminex Therapeutics, Inc.

非在研机构-

权益机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C32H68N6O2

InChIKeyUSNCWPSRPOWEBG-SSEXGKCCSA-N

CAS号441022-64-6

关联

5

项与 AMXT-1501 相关的临床试验

NCT06465199

/ Not yet recruiting临床1/2期IIT

A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 Followed by a Randomized Controlled Trial of DFMO With or Without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas

The purpose of this study is to evaluate the investigational drug AMXT 1501 (a pill taken by mouth) in combination with the drug difluoromethylornithine (DFMO) for infusion administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been placed during a surgery into one of your veins). An investigational drug is one that has not been approved by the U.S. Food & Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat.
The goals of this part of the study are:
* Establish a recommended dose of AMXT 1501 in combination with DFMO for infusion
* Test the safety and tolerability of AMXT 1501 in combination with DFMO for infusion in patients with cancer
* To determine the activity of study treatments chosen based on:
* How each subject responds to the study treatment
* How long a subject lives without their disease returning/progressing

开始日期2025-10-01

申办/合作机构

Hershey Medical Center

[+1]

NCT05717153

/ Recruiting早期临床1期IIT

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501

This early phase I trial studies brain tumor (glioma) metabolism in response to eflornithine (DFMO) and polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) in patients with diffused or high grade glioma. Brain tumors use and produce certain molecules to survive and grow. DFMO is an irreversible inhibitor of ornithine decarboxylase, the enzyme catalyzing polyamine synthesis. AMXT 1501 is a polyamine transport inhibitor which prevents uptake of polyamines from the extracellular environment. This trial is being done to analyze how DFMO and AMXT 1501 affect brain tumor metabolism based on the molecules in the tumor's fluid.

开始日期2023-10-01

申办/合作机构

Mayo Clinic

[+1]

NCT05500508

/ Terminated临床1/2期

A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer

A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.

开始日期2022-11-29

申办/合作机构

Aminex Therapeutics, Inc.

100 项与 AMXT-1501 相关的临床结果

登录后查看更多信息

100 项与 AMXT-1501 相关的转化医学

登录后查看更多信息

100 项与 AMXT-1501 相关的专利（医药）

登录后查看更多信息

20

项与 AMXT-1501 相关的文献（医药）

2025-06-15·International Journal of Cancer

Polyamine depletion limits progression of acute leukaemia

Article

作者: Norris, Murray D. ; Verhelst, Steven H. L. ; Gao, Weiman ; Burns, Mark R. ; Tanaka, Katsunori ; Haber, Michelle ; Karsa, Ayu ; Mayoh, Chelsea ; Somers, Klaartje ; Lock, Richard B. ; Spurling, Dayna ; Xiao, Lin ; Kotecha, Rishi S. ; Azfar, Mujahid ; Cheung, Laurence C. ; Vangheluwe, Peter ; Bongers, Angelika ; Guo, Xinyi ; Karsa, Mawar ; Ronca, Emma

AbstractCancer cells are addicted to polyamines, polycations essential for cellular function. While dual targeting of cellular polyamine biosynthesis and polyamine uptake is under clinical investigation in solid cancers, preclinical and clinical studies into its potential in haematological malignancies are lacking. Here we investigated the preclinical efficacy of polyamine depletion in acute leukaemia. The polyamine biosynthesis inhibitor difluoromethylornithine (DFMO) inhibited growth of a molecularly diverse panel of acute leukaemia cell lines, while non‐malignant cells were unaffected. Responsiveness to DFMO was linked to decreased levels of its molecular target, the rate‐limiting polyamine biosynthesis enzyme ODC1, and of the polyamine transporters ATP13A2 and ATP13A3. DFMO increased polyamine uptake and upregulated expression of polyamine transporters in acute leukaemia cells, a compensatory effect abolished by treatment with the polyamine transport inhibitor AMXT 1501. This drug, currently in a phase 1 clinical trial in solid tumours in combination with DFMO, potentiated the inhibitory effects of DFMO, and their combination synergistically inhibited the growth of acute leukaemia cell lines by inducing apoptosis. DFMO and AMXT 1501 limited disease progression in highly aggressive xenograft models of infant KMT2A‐rearranged leukaemia, even when treatment was initiated at high disease burden. Increased expression of c‐MYC was associated with enhanced sensitivity to the combination of DFMO and AMXT 1501, suggesting this oncoprotein as a potential predictive marker of response to the drug combination. In conclusion, targeting polyamine biosynthesis and polyamine uptake limits disease progression in models of acute leukaemia, supporting further preclinical and clinical investigation into this approach for acute leukaemia.

2025-03-01·Molecular Oncology

The polyamine transporter ATP13A3 mediates difluoromethylornithine‐induced polyamine uptake in neuroblastoma

Article

作者: Xiao, Lin ; Guo, Xinyi ; Norris, Murray D. ; Mayoh, Chelsea ; Ronca, Emma ; Pandher, Ruby ; Verhelst, Steven H. L. ; Bongers, Angelika ; Gao, Weiman ; Van den Haute, Chris ; Karsa, Ayu ; Burns, Mark R. ; Karsa, Mawar ; Azfar, Mujahid ; Vangheluwe, Peter ; Haber, Michelle ; Schoofs, Arthur ; Fayt, Youri ; Somers, Klaartje ; Spurling, Dayna

High‐risk neuroblastomas, often associated with MYCN protooncogene amplification, are addicted to polyamines, small polycations vital for cellular functioning. We have previously shown that neuroblastoma cells increase polyamine uptake when exposed to the polyamine biosynthesis inhibitor difluoromethylornithine (DFMO), and this mechanism is thought to limit the efficacy of the drug in clinical trials. This finding resulted in the clinical development of polyamine transport inhibitors, including AMXT 1501, which is presently under clinical investigation in combination with DFMO. However, the mechanisms and transporters involved in DFMO‐induced polyamine uptake are unknown. Here, we report that knockdown of ATPase 13A3 (ATP13A3), a member of the P5B‐ATPase polyamine transporter family, limited basal and DFMO‐induced polyamine uptake, attenuated MYCN‐amplified and non‐MYCN‐amplified neuroblastoma cell growth, and potentiated the inhibitory effects of DFMO. Conversely, overexpression of ATP13A3 in neuroblastoma cells increased polyamine uptake, which was inhibited by AMXT 1501, highlighting ATP13A3 as a key target of the drug. An association between high ATP13A3 expression and poor survival in neuroblastoma further supports a role of this transporter in neuroblastoma progression. Thus, this study identified ATP13A3 as a critical regulator of basal and DFMO‐induced polyamine uptake and a novel therapeutic target for neuroblastoma.

2024-12-31·Emerging Microbes & Infections

AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria

Article

作者: Wen, Zewen ; Zheng, Jinxin ; Xiong, Yanpeng ; Zhang, Fan ; Liu, Xiaoju ; Liu, Xiaoming ; Lin, Zhiwei ; Meng, Qingyin ; Yu, Zhijian ; Deng, Qiwen ; Li, Peiyu

The rapid proliferation of multidrug-resistant (MDR) bacterial pathogens poses a serious threat to healthcare worldwide. Carbapenem-resistant (CR) Enterobacteriaceae, which have near-universal resistance to available antimicrobials, represent a particularly concerning issue. Herein, we report the identification of AMXT-1501, a polyamine transport system inhibitor with antibacterial activity against Gram-positive and -negative MDR bacteria. We observed minimum inhibitory concentration (MIC)₅₀/MIC₉₀ values for AMXT-1501 in the range of 3.13-12.5 μM (2.24-8.93 μg /mL), including for methicillin-resistant Staphylococcus aureus (MRSA), CR Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. AMXT-1501 was more effective against MRSA and CR E. coli than vancomycin and tigecycline, respectively. Subinhibitory concentrations of AMXT-1501 reduced the biofilm formation of S. aureus and Enterococcus faecalis. Mechanistically, AMXT-1501 exposure damaged microbial membranes and increased membrane permeability and membrane potential by binding to cardiolipin (CL) and phosphatidylglycerol (PG). Importantly, AMXT-1501 pressure did not induce resistance readily in the tested pathogens.

100 项与 AMXT-1501 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
子宫内膜癌	临床3期	美国	Aminex Therapeutics, Inc.	2022-11-29
子宫内膜癌	临床3期	澳大利亚	Aminex Therapeutics, Inc.	2022-11-29
腹膜恶性间皮瘤	临床3期	美国	Aminex Therapeutics, Inc.	2022-11-29
腹膜恶性间皮瘤	临床3期	澳大利亚	Aminex Therapeutics, Inc.	2022-11-29
非小细胞肺癌	临床3期	澳大利亚	Aminex Therapeutics, Inc.	2022-11-29
非小细胞肺癌	临床3期	美国	Aminex Therapeutics, Inc.	2022-11-29
乳头状甲状腺癌	临床3期	澳大利亚	Aminex Therapeutics, Inc.	2022-11-29
乳头状甲状腺癌	临床3期	美国	Aminex Therapeutics, Inc.	2022-11-29
胃癌	临床3期	澳大利亚	Aminex Therapeutics, Inc.	2022-11-29
胃癌	临床3期	美国	Aminex Therapeutics, Inc.	2022-11-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03536728 (986, SITC2024)	临床1期	晚期恶性实体瘤 \| 晚期癌症	-	AMXT 1501	廠築積壓窪獵鏇醖衊鏇(築築淵鑰網簾繭糧廠淵) = 36 reports 壓構鹹鏇鹽築鹹遞顧構 (憲膚壓艱簾願糧鏇鏇築 ) 更多	积极	2024-11-05